Efficacy and safety of 10‐deazaaminopterin in the treatment of rheumatoid arthritis: A one‐year continuation, double‐blind study

Academic Article

Abstract

  • Objective. To determine the long‐term safety and efficacy of 10‐deazaaminopterin (10‐DAM) in the treatment of rheumatoid arthritis (RA). Methods. A 1‐year continuation of an initial 15‐week randomized, double‐blind clinical trial of 10‐DAM and methotrexate (MTX). Results. 10‐DAM (n = 10) and MTX (n = 8) had comparable safety and efficacy profiles. One 10‐DAM—treated and 2 MTX‐treated patients experienced transient side effects; 1 MTX‐treated patient experienced recurrent nausea and discontinued MTX. Conclusion. 10‐DAM appears to be as beneficial and as safe as MTX for the treatment of RA. Copyright © 1992 American College of Rheumatology
  • Digital Object Identifier (doi)

    Author List

  • Alarcón GS; Castañeda O; Ferrándiz M; Krumdieck CL; Koopman WJ
  • Start Page

  • 1318
  • End Page

  • 1321
  • Volume

  • 35
  • Issue

  • 11